CN105705641B - 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 - Google Patents

涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Download PDF

Info

Publication number
CN105705641B
CN105705641B CN201480040538.3A CN201480040538A CN105705641B CN 105705641 B CN105705641 B CN 105705641B CN 201480040538 A CN201480040538 A CN 201480040538A CN 105705641 B CN105705641 B CN 105705641B
Authority
CN
China
Prior art keywords
cells
ifn
cytokines
cell
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480040538.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105705641A (zh
Inventor
J·塔威尼尔
J·堡丁克
S·格尔罗
G·尤则
F·保罗
Y·博达特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Montpellier
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier filed Critical Universiteit Gent
Priority to CN201911159381.7A priority Critical patent/CN110835376B/zh
Publication of CN105705641A publication Critical patent/CN105705641A/zh
Application granted granted Critical
Publication of CN105705641B publication Critical patent/CN105705641B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480040538.3A 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Active CN105705641B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911159381.7A CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306034.3 2013-07-18
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911159381.7A Division CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Publications (2)

Publication Number Publication Date
CN105705641A CN105705641A (zh) 2016-06-22
CN105705641B true CN105705641B (zh) 2021-07-13

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911159381.7A Active CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
CN201480040538.3A Active CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911159381.7A Active CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3022305B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN110835376B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2757501T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG10201808738WA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CA3013558C (en) 2016-02-05 2024-11-12 Universiteit Gent CD8 LIAISON OFFICERS
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CA3050601A1 (en) * 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
CN111328286B (zh) 2017-08-09 2024-08-23 奥里尼斯生物科学有限公司 Pd-1和pd-l1结合剂
KR102793204B1 (ko) 2017-08-09 2025-04-08 오리오니스 바이오사이언시스 인코포레이티드 Clec9a 결합제 및 그의 용도
EP3703723A4 (en) 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
WO2022011005A1 (en) * 2020-07-07 2022-01-13 Orionis Biosciences, Inc. Immunostimulatory adjuvants
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL308018B2 (en) 2021-04-30 2025-04-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for altered MHC expression
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2055445T3 (es) * 1989-08-22 1994-08-16 Immunex Corp Proteinas de fusion que comprenden gm-csf e il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2008014612A1 (en) 2006-08-02 2008-02-07 Mcgill University Fusion proteins and methods for modulation of immune response
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
CN103880965B (zh) 2007-09-21 2018-02-16 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
JP2012510806A (ja) 2008-12-08 2012-05-17 コンプリクス エン ヴェー 単鎖逆平行コイルドコイルタンパク質
AR077879A1 (es) 2009-08-17 2011-09-28 Roche Glycart Ag Inmunoconjugados dirigidos
CA2773426A1 (en) 2009-09-10 2011-03-17 Cytos Biotechnology Ag Use of interleukin-1 beta mutein conjugates in the treatment of diabetes
AU2010313112B2 (en) * 2009-11-02 2014-06-26 The Regents Of The University Of California Vault complexes for cytokine delivery
WO2011079077A1 (en) * 2009-12-23 2011-06-30 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CA2796706A1 (en) * 2010-04-22 2011-10-27 The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center High affinity leptins and leptin antagonists
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
US9534056B2 (en) 2011-06-06 2017-01-03 Immungene Inc Engineered TAA antibody-TNFSF member ligand fusion molecules
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
ES2694180T3 (es) * 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
WO2013134138A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
IL251822B2 (en) * 2014-10-29 2023-03-01 Teva Pharmaceuticals Australia Pty Ltd Variants of interferon alpha-2-b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Differential responses to IFN-α subtypes in human T cells and dendritic cells;Hilkens CM et al;《The Journal of Immunology》;20031115;第171卷(第10期);5255-5263 *
XCL1 and XCR1 in the immune system;Yu Lei et al;《Microbes and Infection》;20111031;第14卷(第3期);262-267 *

Also Published As

Publication number Publication date
JP6580037B2 (ja) 2019-09-25
AU2018203868A1 (en) 2018-06-21
KR102322510B1 (ko) 2021-11-08
HK1252831A1 (en) 2019-06-06
EP3022305B1 (en) 2017-11-01
IL243451A0 (en) 2016-03-31
US20180155404A1 (en) 2018-06-07
JP2020002155A (ja) 2020-01-09
MX2016000611A (es) 2016-09-29
CN105705641A (zh) 2016-06-22
EP3022305A2 (en) 2016-05-25
CA2917937C (en) 2022-11-01
WO2015007536A2 (en) 2015-01-22
KR20160108291A (ko) 2016-09-19
ES2657060T3 (es) 2018-03-01
SG10201808738WA (en) 2018-11-29
US12410222B2 (en) 2025-09-09
WO2015007536A3 (en) 2015-03-19
JP2016525516A (ja) 2016-08-25
CN110835376A (zh) 2020-02-25
AU2018203868B2 (en) 2019-12-05
ES2757501T3 (es) 2020-04-29
EP3299466B1 (en) 2019-09-11
IL243451B (en) 2019-10-31
US20190010199A1 (en) 2019-01-10
EP3299466A1 (en) 2018-03-28
BR112016001036A2 (pt) 2017-10-24
JP6853317B2 (ja) 2021-03-31
DK3299466T3 (da) 2019-11-18
CA2917937A1 (en) 2015-01-22
SG11201600163VA (en) 2016-02-26
CN110835376B (zh) 2023-08-04
AU2014292371A1 (en) 2016-02-04
US10640542B2 (en) 2020-05-05
US11358997B2 (en) 2022-06-14
AU2014292371B2 (en) 2018-03-29
MX375441B (es) 2025-03-06
BR112016001036B1 (pt) 2023-02-23
US20230054612A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
US12410222B2 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
KR102609197B1 (ko) 인터류킨 15 단백질 복합체 및 그의 용도
CN110437339A (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
KR100862136B1 (ko) 인터루킨-18 변이체, 이들의 생산 및 용도
IL184423A (en) Homogeneous preparations of il-31, process for their production and formulations comprising them
CN116096730A (zh) 细胞因子结合物
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
Zhan et al. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs
JPH09512165A (ja) インターロイキン１５
HK1252831B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069A1 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
Xiong et al. Cloning and expression of rabbit interleukin-15
US12134635B1 (en) Interleukin 18 (IL-18) variants and fusion proteins comprising same
JP3689111B2 (ja) インターロイキン１５

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Ghent

Applicant after: Univ Gent

Applicant after: Universiteit Gent

Applicant after: Centre National De La Recherche Scientifique

Applicant after: Universite De Montpellier

Applicant after: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

Address before: Ghent

Applicant before: Univ Gent

Applicant before: Universiteit Gent

Applicant before: Centre National De La Recherche Scientifique

Applicant before: Univ. Montpellier II

Applicant before: CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

GR01 Patent grant
GR01 Patent grant